Drug Search Results
More Filters [+]

AZD-3199

Alternative Names: azd-3199, azd3199, azd 3199
Latest Update: 2016-12-21
Latest Update Note: Clinical Trial Update

Product Description

AZD3199 was investigated as an inhaled, once-daily uLABA in patients with asthma and COPD.Ê (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330041/)

Mechanisms of Action: LAB Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AZD-3199

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Asthma|Airway Obstruction|Chronic Obstructive Pulmonary Disease

Phase 1: Healthy Volunteers|Chronic Obstructive Pulmonary Disease|Abnormalities, Multiple|Tremor

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Evaluation of PK and PD of AZD3199 in dry powder inhalation formulations in patients with asthma

P2

Completed

Asthma

2012-02-27

D0570C00011

P2

Completed

Asthma

2012-02-01

D0570C00004

P1

Completed

Chronic Obstructive Pulmonary Disease

2011-02-01

GLAD

P2

Completed

Chronic Obstructive Pulmonary Disease

2010-03-19

Recent News Events

Date

Type

Title